<em class="pub-author">EMCDDA,</em> <em class="pub-local">Lisbon,</em> <em class="pub-date"><span class="date-display-single" property="dc:date" datatype="xsd:dateTime" content="2020-12-14T00:00:00+00:00">December 2020</span></em> <div class="summary"> <h2 class="publications-summary">Summary</h2> <div class="field field-name-field-summary field-type-text-long field-label-hidden"><div class="field-items" readability="9"><div class="field-item even" readability="13">The Evidence database is a core component of the EMCDDA’s Best Practice Portal. The portal is a resource for professionals, policymakers and researchers in the drugs field and provides information on the available evidence on drug-related prevention, treatment and harm reduction, focusing on the European context. The evidence is compiled following an explicit methodological process which is described in this document.
Protocol for updating the Evidence database of the Best Practice Portal
DISCLAIMER: Information and opinions reproduced in the articles are the ones of those stating them and it is their own responsibility. Publication in The European Times does not automatically means endorsement of the view, but the right to express it.
DISCLAIMER TRANSLATIONS: All articles in this site are published in English. The translated versions are done through an automated process known as neural translations. If in doubt, always refer to the original article. Thank you for understanding.
More from the author
Report on the risk assessment of N,N-diethyl-2- [[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1Hbenzimidazole- 1-ethanamine (isotonitazene) in accordance with Article...
<div class="publication-attachments pdf"> <strong>Download as PDF</strong> </div> <div class="main-subject"><h3 class="field-label"><i class="fa fa-tag"/> Main subject: </h3><p class="field-items"><span class="field-item"><a href="/topic/best-practice">best practice</a></span></p></div>